Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081006 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL1979130 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL9142042 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL6887353 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL2589566 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL8970336 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL12552334 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL8970347 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL9141461 | 0.89 | SLC29A1 (0.72) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL13265481 | 0.88 | SLC29A1 (0.67) | SLC29A1ADORA1ADORA2AADORA2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0415731-B1 | Novel entities for cancer therapy | WELLCOME FOUND (GB) | 2003-04-02 | — | — | EP | claimed |
| EP-0657539-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| EP-0657540-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | claimed |
| CN-122028027-A | ESIM identification method and related device | 华为技术有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12626021-B2 | Secure element with access rule application ARA | GIESECKE+DEVRIENT MOBILE SECURITY GERMANY GMBH (DE) | 2026-05-12 | — | — | US | disclosed |
| US-12563381-B2 | Method of managing subscriber identity module (SIM) application and system for using the same | RAKUTEN SYMPHONY, INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4109840-B1 | METHOD FOR SESSION CREATION AND RELATED EQUIPMENT | BEIJING UNISOC COMM TECH CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12518016-B2 | Information processing device, information processing method, mobile terminal, and information processing system | FELICA NETWORKS, INC. (JP) | 2026-01-06 | — | — | US | disclosed |
| EP-4659467-A1 | METHOD OF MANAGING SUBSCRIBER IDENTITY MODULE (SIM) APPLICATION AND SYSTEM FOR USING THE SAME | Rakuten Symphony, Inc. (JP) | 2025-12-10 | — | — | EP | disclosed |
| EP-4445285-B1 | SECURE ELEMENT WITH ACCESS RULES APPLICATION | GIESECKE DEVRIENT MOBILE SECURITY GERMANY GMBH (DE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250213724-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | CureVac SE (DE) | 2025-07-03 | — | — | US | disclosed |
| EP-0657541-A1 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| US-5424295-A | Useful in treatment of varicella-zoster virus infections | BURROUGHS WELLCOME CO. (US) | 1995-06-13 | — | — | US | disclosed |
| US-5393883-A | Ribonucleotide reductase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | disclosed |
| US-5175165-A | Acyclovir and a thiocarbonohydrazone ribonucleotide reductase inhibitor for treatment of herpes virus | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | disclosed |
| EP-0415731-A2 | Novel entities for cancer therapy | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-06 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
| EP-0294114-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12563381-B2 | Method of managing subscriber identity module (SIM) application and system for using the same | SAMM50, STMN1, STMN2 | SLC29A1 4131/4885ADORA1 4884/4885ADORA2A 4883/4885 |
| US-20250213724-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | RNASE1, RNMT, TRDMT1 | SLC29A1 919/4885ADORA1 1918/4885ADORA2A 1926/4885 |
| US-12626021-B2 | Secure element with access rule application ARA | SARAF, RAE1, EPHA8 | SLC29A1 689/4885ADORA1 548/4885ADORA2A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.